VEGFA and lung cancer: Several studies demonstrated that angiogenesis and the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors and their receptors correlate with a less favourable clinical outcome for lung cancer patients; yet clinical trials of agents that target these pathways alone have been disappointing (Bremnes et al, 2006).